Hepatocyte–stellate cell synapse in alcohol-induced steatosis: another role for endocannabinoids

A new study demonstrates a novel role for an endocannabinoid in promoting hepatocyte steatosis. The study describes a mode of bidirectional communication between the alcohol-injured hepatocyte and the glutamate-activated hepatic stellate cell. This intercellular communication represents a novel targetable pathogenic mechanism that could lead to new strategies to prevent fatty liver disease progression to cirrhosis.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Pathogenic roles of endocannabinoids in liver diseases.


  1. 1.

    Asrani, S. K. et al. Burden of liver diseases in the world. J. Hepatol. 70, 151–171 (2019).

  2. 2.

    McPherson, S. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol. 62, 1148–1155 (2015).

  3. 3.

    Parker, R. et al. Natural history of histologically proven alcohol-related liver disease: a systematic review. J. Hepatol. 71, 586–593 (2019).

  4. 4.

    Louvet, A. & Mathurin, P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat. Rev. Gastroenterol. Hepatol. 12, 231–242 (2015).

  5. 5.

    Dam-Larsen, S. et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 53, 750–755 (2004).

  6. 6.

    Choi, W. M. et al. Glutamate signaling in hepatic stellate cells drives alcoholic steatosis. Cell Metab. (2019).

  7. 7.

    Spooren, W. et al. Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav. Pharmacol. 14, 257–277 (2003).

  8. 8.

    Caraceni, P. et al. The endocannabinoid system and liver diseases. J. Neuroendocrinol. 20, 47–52 (2008).

  9. 9.

    Nguyen, T. et al. Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: current approaches for therapeutics development. Curr. Top. Med. Chem. 19, 1418–1435 (2019).

  10. 10.

    Godlewski, G. et al. Targeting peripheral CB1 receptors reduces ethanol intake via a gut-brain axis. Cell Metab. 29, 1320–1333 (2019).

Download references


R.B. is supported by NIH/NIAAA grants AA026972, AA026978 and AA026264, and by NIH/NIDDK grant P30DK120531.

Author information

Correspondence to Ramon Bataller.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Argemi, J., Bataller, R. Hepatocyte–stellate cell synapse in alcohol-induced steatosis: another role for endocannabinoids. Nat Rev Gastroenterol Hepatol 17, 5–6 (2020).

Download citation